Clinical Trial Update: Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A [Phase 4]

View source ↗

Summary

Phase 4 dose-response study of recombinant Factor VIII manufactured protein-free (rAHF-PFM) in patients with Hemophilia A has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• recombinant Factor VIII manufactured protein-free (rAHF-PFM) (recombinant Factor VIII manufactured protein-free)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2011-01-13